HC Wainwright Forecasts LifeMD’s Q1 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Investment analysts at HC Wainwright reduced their Q1 2026 EPS estimates for LifeMD in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.05 for the quarter, down from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.47 EPS.

A number of other equities analysts have also recently commented on the stock. KeyCorp cut their price target on shares of LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Wednesday. Wall Street Zen cut shares of LifeMD from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. BTIG Research upped their price objective on shares of LifeMD from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, June 18th. Finally, Lake Street Capital cut their price objective on shares of LifeMD from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.86.

LifeMD Price Performance

LFMD stock opened at $6.82 on Friday. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.77. LifeMD has a one year low of $3.99 and a one year high of $15.84. The stock has a market cap of $323.40 million, a PE ratio of -32.48 and a beta of 1.72. The firm has a 50 day simple moving average of $11.86 and a two-hundred day simple moving average of $8.49.

Insider Activity

In other LifeMD news, CFO Marc David Benathen sold 50,000 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $14.01, for a total transaction of $700,500.00. Following the completion of the sale, the chief financial officer owned 339,554 shares of the company’s stock, valued at $4,757,151.54. This represents a 12.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Stefan Galluppi sold 85,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $12.38, for a total transaction of $1,052,300.00. Following the sale, the insider directly owned 80,449 shares of the company’s stock, valued at $995,958.62. The trade was a 51.38% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 275,000 shares of company stock worth $3,564,550. 18.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Royce & Associates LP raised its holdings in LifeMD by 3.5% in the 1st quarter. Royce & Associates LP now owns 1,155,231 shares of the company’s stock worth $6,284,000 after purchasing an additional 39,240 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in LifeMD by 5.4% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company’s stock worth $5,342,000 after purchasing an additional 50,600 shares in the last quarter. Geode Capital Management LLC raised its holdings in LifeMD by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 925,173 shares of the company’s stock worth $12,603,000 after purchasing an additional 67,440 shares in the last quarter. Millennium Management LLC raised its holdings in LifeMD by 17.1% in the 4th quarter. Millennium Management LLC now owns 885,987 shares of the company’s stock worth $4,386,000 after purchasing an additional 129,327 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of LifeMD by 45.2% in the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company’s stock worth $2,524,000 after acquiring an additional 158,796 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.